Seefunge Pharmaceutical Technology

Seefunge is a clinical-stage biotechnology company specializing in the development of targeted protein degradation (TPD) therapies, with a primary focus on molecular glues and PROTACs. The company leverages its proprietary discovery platform to identify and optimize small molecules that can degrade previously "undruggable" protein targets associated with cancer and immunological disorders. Its lead program, SFG-001, is a potent molecular glue degrader of GSPT1 currently undergoing Phase 1 clinical trials for advanced solid tumors and hematological malignancies. Headquartered in Suzhou, China, Seefunge is supported by a strong syndicate of investors including Lilly Asia Ventures and Qiming Venture Partners. The company aims to redefine treatment paradigms by harnessing the body's natural protein disposal system to eliminate disease-causing proteins.